BioPharma Dive
Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a mandate on rare disease flexibility.
BioPharma Dive
Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a mandate on rare disease flexibility.
BioPharma Dive
Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a mandate on rare disease flexibility.